 "Hester Biosciences surges 10% on launching PPR and goat pox vaccine")
Hester Biosciences is locked in upper circuit of 10% at Rs 488 on the National Stock Exchange (NSE) after the pharmaceutical company launches its PPR (Peste Des Petits Ruminants) vaccine and Goat Pox vaccine.
PPR vaccine is to be given annually to sheep and goats. PPR disease causes dysentery and death of the animal. It is therefore a disease of high economical importance worldwide.
With the launch of these vaccines as well as being the second largest poultry vaccine manufacturer in India, Hester has positioned itself to capitalise on upcoming opportunities in the animal health care industry globally as well as in India,” Hester Biosciences said in a media release.
“The world market for PPR vaccine is slated to be for Rs 300 crore annually. The Indian market is slated to be Rs 40 crore annually. The PPR vaccine will contribute toward also the disease eradication programs of the Government of India,” said Mr. Rajiv Gandhi, CEO & MD, Hester Biosciences.
Till 1006 hours, a combined 14,617 shares changed hands and there are pending buy orders for 3,339 shares on the NSE and BSE.
PPR vaccine is to be given annually to sheep and goats. PPR disease causes dysentery and death of the animal. It is therefore a disease of high economical importance worldwide.
With the launch of these vaccines as well as being the second largest poultry vaccine manufacturer in India, Hester has positioned itself to capitalise on upcoming opportunities in the animal health care industry globally as well as in India,” Hester Biosciences said in a media release.
“The world market for PPR vaccine is slated to be for Rs 300 crore annually. The Indian market is slated to be Rs 40 crore annually. The PPR vaccine will contribute toward also the disease eradication programs of the Government of India,” said Mr. Rajiv Gandhi, CEO & MD, Hester Biosciences.
Till 1006 hours, a combined 14,617 shares changed hands and there are pending buy orders for 3,339 shares on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%